About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
IP: José Raul Herance Camacho Collaborators: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Clara Ramírez Serra, Azahara Maria Palomar Muñoz, Cristina Gamez Cenzano, Jana Vidal Otero, Carolina Aparicio Gomez, Alberto Roque Pérez, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán, Emily Betancourt Fernández, Martha Sahylí Ortega Pijeira, Maria Nazarena Pizzi, Enrique Franky Vargas Funding agency: Instituto de Salud Carlos III Funding: 252500 Reference: PI24/01356 Duration: 01/01/2025 - 31/12/2027
IP: Rafael Simó Canonge Collaborators: Olga Simó Servat, Marta Garrido Marin, Miguel Angel Zapata Victori Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 602031 Reference: CPP2023-010602 Duration: 01/10/2024 - 30/09/2027
IP: Andreea Ciudin Mihai Collaborators: Manuel Escobar Amores, Nuria Roson Gradaille, Fiorella Ximena Palmas Candia, Aitor Rodriguez Martinez, Marta Comas Martinez, Enzamaría Fidilio Meli Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 431460 Reference: CPP2023-010524 Duration: 01/11/2024 - 30/10/2027
IP: Inmaculada Fuentes Camps Collaborators: Antonio Moreno Galdó, Rafael Simó Canonge, Ariadna Martín Balcells, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Gemma Vona Giralt, Paula Isabel Roldan Caballero Funding agency: Instituto de Salud Carlos III Funding: 274920 Reference: PT23/00062 Duration: 01/01/2024 - 31/12/2026
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The document provides recommendations for identifying people who are candidates for these treatments and for guiding their implementation and follow-up in clinical practice.
The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.
